Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

28.85 -0.15 (-0.52%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign
SOURCE: Alkermes 
Via 3BL Media
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Biogen isn't the only company whose shares should benefit from a breakthrough drug. 
Via The Motley Fool
Alkermes Celebrates Alcoholics Anonymous Founders Day
SOURCE: Alkermes 
Via 3BL Media
The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award
SOURCE: Alkermes 
Via 3BL Media
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
Alkermes Supports Mental Health Clinical Research
SOURCE: Alkermes 
Via 3BL Media
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Agios Pharmaceuticals, Inc... 
Via Benzinga
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
Alkermes: Diversity Strengthens Our Culture
SOURCE: Alkermes 
Via 3BL Media
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
"I'm Incredibly Proud to Work at a Company Whose Mission Is To Help Families Like Mine"
SOURCE: Alkermes 
Via 3BL Media
Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med
The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Alkermes Inspiration Grants® 2021 Applications Are Now Open
SOURCE: Alkermes 
Via 3BL Media
Alkermes Celebrates Mental Health Month
SOURCE: Alkermes 
Via 3BL Media
Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
SOURCE: Alkermes 
Via 3BL Media
Why Shares of Alkermes Rose 18% Last Month
An agreement with an activist investor capped a busy month. 
Via The Motley Fool
Want to Make Money in Biotech? Do This First
Keeping track of upcoming events is important. 
Via The Motley Fool
Topics Regulatory Compliance
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
SOURCE: Alkermes 
Via 3BL Media
Topics Regulatory Compliance
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Alkermes PLC (ALKS) Q1 2021 Earnings Call Transcript
ALKS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence
SOURCE: Alkermes 
Via 3BL Media
Alkermes: Q1 Earnings Insights
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11,... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy
Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.